Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Corbus Pharmaceuticals (NASDAQ: CRBP) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, scheduled for January 13-16, 2025, in San Francisco, CA. CEO Yuval Cohen, Ph.D., will deliver a presentation on January 16, 2025, at 11:15 a.m. PST and will be available for one-on-one investor meetings during the conference.

The prestigious healthcare conference is an invitation-only event, and interested parties are advised to contact their J.P. Morgan representative for attendance details.

News Market Reaction

-1.38%

1 alert

-1.38% News Effect

On the day this news was published, CRBP declined 1.38%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

NORWOOD, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will be participating in the 43^rd Annual J.P. Morgan Healthcare Conference, to be held January 13-16, 2025 in San Francisco, CA. Dr. Cohen will be presenting and attending investor meetings.

43^rd Annual J.P. Morgan Healthcare Conference
Format: Presentation and one-on-one investor meetings
Presentation Date: January 16, 2025
Presentation Time 11:15 a.m. PST

The J.P. Morgan Healthcare Conference is invitation only. Those interested in attending should contact their J.P. Morgan representative for more information.

About Corbus
Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook.

Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential,” "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies.

INVESTOR CONTACT:

Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
Sean.moran@corbuspharma.com

Bruce Mackle
Managing Director
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com

FAQ

When is Corbus Pharmaceuticals (CRBP) presenting at the 2025 J.P. Morgan Healthcare Conference?

Corbus Pharmaceuticals will present on January 16, 2025, at 11:15 a.m. PST during the conference in San Francisco.

Who will represent CRBP at the 2025 J.P. Morgan Healthcare Conference?

Dr. Yuval Cohen, Chief Executive Officer of Corbus Pharmaceuticals, will represent the company at the conference.

What type of activities will CRBP participate in at the J.P. Morgan Healthcare Conference 2025?

CRBP will participate in both a presentation and one-on-one investor meetings during the conference.

How can investors attend CRBP's presentation at the J.P. Morgan Healthcare Conference?

The conference is invitation-only. Interested parties must contact their J.P. Morgan representative for attendance information.

What dates will the 43rd J.P. Morgan Healthcare Conference run in 2025?

The conference will run from January 13-16, 2025, in San Francisco, CA.